Kardogrel is developed by University of Pecs.

What development phase is Kardogrel in?

Kardogrel is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Kardogrel

University of Pecs · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Kardogrel
Also known as	generic clopidogrel = Kardogrel
Sponsor	University of Pecs
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Prasugrel Versus Adjusted High-dose Clopidogrel to TREAT High On-clopidogrel Platelet Reactivity in Acute Coronary Syndrome Patients After PCI (Phase 4)
Comparison of the Generic and Original Formulation of Clopidogrel Regarding the Potency of Platelet Inhibition in Patients After PCI (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kardogrel CI brief — competitive landscape report
Kardogrel updates RSS · CI watch RSS
University of Pecs portfolio CI